Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

AstraZeneca and Bristol-Myers Squibb collaborate on type 2 diabetes compounds

Jan. 16, 2007

Preclinical characterization of sergliflozin, a novel selective SGLT2 inhibitor

Jan. 16, 2007

PBI-1402 studied in anemic patients with chronic kidney disease

Jan. 15, 2007

Fispemifene significantly increases testosterone in androgen-deficient men

Jan. 15, 2007

Recent patents report novel contraceptives and therapeutic agents for sexual dysfunction

Jan. 15, 2007

InteKrin licenses INT-131 from Amgen

Jan. 12, 2007

Biopure receives opinion letter in U.K. on Hemopure MAA

Jan. 12, 2007

New antidiabetic agents disclosed in recent patent literature

Jan. 12, 2007

Acid sphingomyelinase replacement therapy to be evaluated in Niemann-Pick disease

Jan. 12, 2007

Elaprase approved in E.U. for Hunter's syndrome

Jan. 11, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...